• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Covance Revenues Up, Maintains Guidance

Covance Revenues Up, Maintains Guidance

January 29, 2009
CenterWatch Staff

Covance released strong fourth quarter and year end 2008 financial results late Wednesday with revenue increases in both early and late-stage development segments.

Total fourth quarter net revenues were $439 million, up 6.7% from the same period last year. Net income for the quarter was $45.6 million, down 2.5% year over year, with diluted earnings per share of $0.72, down 0.6% from the same quarter last year.

Net revenues for early development were $214.2 million, up 3.1% from $207.9 million in the fourth quarter of 2007. Late-stage development revenues were $224.4 million, up 10.5% from $203.1 million in the same period last year.

While both early- and late-stage development revenues were up, profitability for the early-stage segment declined to 21.4% from 24.8% for the fourth quarter last year.

"Reduced demand in our Early Development segment from a combination of a lower level of new project initiations and increased project delays in our toxicology and clinical pharmacology services led to a sequential decline in segment revenue and operating income," said Covance chairman and CEO Joe Herring in a company release.

Covance’s late-stage development segment increased its operating margin from 16% in Q4 2007 to 19.6% in the fourth quarter of 2008.

Because of the strength in its late-stage development segment, Covance maintained its 2009 full-year revenue growth guidance of 5% to 10% year over year and earnings per share in the range of $3 to $3.20.

In afternoon trading, Covance’s share prices were up almost 8% to $39.72.

Upcoming Events

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

  • White House

    Trial Stakeholders Advise White House on Emergency Research Infrastructure

  • SurveywBlueBackground-360x240.png

    Stress Levels Continue to Climb in Healthcare Workforce, Survey Finds

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing